FR13C0032I1 - - Google Patents

Info

Publication number
FR13C0032I1
FR13C0032I1 FR13C0032C FR13C0032I1 FR 13C0032 I1 FR13C0032 I1 FR 13C0032I1 FR 13C0032 C FR13C0032 C FR 13C0032C FR 13C0032 I1 FR13C0032 I1 FR 13C0032I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0032(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0032I1 publication Critical patent/FR13C0032I1/fr
Application granted granted Critical
Publication of FR13C0032I2 publication Critical patent/FR13C0032I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR13C0032C 2002-11-07 2013-06-19 REMEDY FOR OVERACTIVE BLADDER COMPRISING ANILIDE DERIVATIVE OF ACETIC ACID AS ACTIVE INGREDIENT Active FR13C0032I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
PCT/JP2003/014065 WO2004041276A1 (en) 2002-11-07 2003-11-04 Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

Publications (2)

Publication Number Publication Date
FR13C0032I1 true FR13C0032I1 (en) 2013-08-09
FR13C0032I2 FR13C0032I2 (en) 2014-03-07

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0032C Active FR13C0032I2 (en) 2002-11-07 2013-06-19 REMEDY FOR OVERACTIVE BLADDER COMPRISING ANILIDE DERIVATIVE OF ACETIC ACID AS ACTIVE INGREDIENT

Country Status (28)

Country Link
US (5) US20060115540A1 (en)
EP (1) EP1559427B1 (en)
JP (1) JP3815496B2 (en)
KR (1) KR100967070B1 (en)
CN (1) CN100406011C (en)
AT (1) ATE500827T1 (en)
AU (1) AU2003284700B2 (en)
BE (1) BE2013C040I2 (en)
BR (1) BR0316080A (en)
CA (1) CA2503570C (en)
CY (2) CY1111399T1 (en)
DE (1) DE60336334D1 (en)
DK (1) DK1559427T3 (en)
ES (1) ES2360353T3 (en)
FR (1) FR13C0032I2 (en)
HU (1) HUS1300027I1 (en)
IL (1) IL168121A (en)
LU (1) LU92218I2 (en)
MX (1) MXPA05004925A (en)
NL (1) NL300599I2 (en)
NO (2) NO334948B1 (en)
NZ (1) NZ539577A (en)
PL (1) PL211687B1 (en)
PT (1) PT1559427E (en)
RU (1) RU2321401C2 (en)
SI (1) SI1559427T1 (en)
WO (1) WO2004041276A1 (en)
ZA (1) ZA200503510B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (en) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical composition for the treatment of stress incontinence and / or mixed incontinence
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
CA2709727A1 (en) 2007-12-21 2009-07-02 Astellas Pharma Inc. Pharmaceutical composition for improving lower urinary tract symptoms
PE20091825A1 (en) * 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
TWI478712B (en) 2008-09-30 2015-04-01 Astellas Pharma Inc Pharmaceutical composition for modified release
WO2010053068A1 (en) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 Novel useful therapeutic agent for lower urinary tract symptom
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8877214B2 (en) * 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2011122524A1 (en) 2010-03-29 2011-10-06 アステラス製薬株式会社 Controlled release pharmaceutical composition
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
US9283210B2 (en) 2011-05-18 2016-03-15 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
JPWO2013147134A1 (en) 2012-03-30 2015-12-14 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
EA201590449A1 (en) 2012-08-31 2015-06-30 Астеллас Фарма Инк. ORAL PREPARED MEDICINE COMPOSITION
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (en) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 Synthesis method of mirabegron
CN103232368B (en) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 A kind of synthetic method of (R)-4-nitrophenethyl-(2-hydroxyl-2-styroyl)-t-butyl carbamate
CN103193658A (en) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 Synthesis method of (R)-2-p-nitrobenzene ethylamine-1-phenethyl alcohol and salt thereof
CN103232352B (en) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (R)-4-(2-(2-hydroxyl-2-phenylethylamine base) ethyl) anilino carboxylate
CN105579057A (en) * 2013-07-23 2016-05-11 阿勒根公司 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
ITMI20131653A1 (en) * 2013-10-07 2015-04-08 Dipharma Francis Srl CRYSTALLINE FORMS OF AN ADRENERGIC AGONIST
RU2550968C1 (en) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Integrated method of treating female patients suffering from chronic recurrent cystitis and refractory overactive bladder
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (en) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 Synthetic method of mirabegron
CN104016877B (en) * 2014-06-13 2017-02-15 南京海融制药有限公司 Acetylaniline compounds and application thereof in preparation of mirabegron
CN104230840A (en) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 Synthesis method of mirabegron
CN106999538A (en) 2014-11-20 2017-08-01 阿勒根公司 Method and composition comprising minirin Yu alpha-2 adrenoceptor antagonist-combination
CN104496841B (en) * 2014-11-26 2017-01-25 南京工业大学 Synthesis method of Mirabegron intermediate
CN104744292A (en) * 2015-03-11 2015-07-01 南京工业大学 Preparation method of -2- ((4-nitrophenylethyl) amino) -2-oxo-1-phenylethyl acetate or derivative thereof
JP2018090490A (en) 2015-03-31 2018-06-14 アステラス製薬株式会社 Mirabegron-containing pharmaceutical composition
JP6618736B2 (en) 2015-09-01 2019-12-11 沢井製薬株式会社 Mirabegron-containing tablet, method for producing mirabegron-containing preparation, and method for producing mirabegron-containing granulated product
CN106278909B (en) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 Post-treatment method of mirabegron intermediate
EP3360866B1 (en) 2017-02-14 2019-01-02 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR102051132B1 (en) * 2017-03-17 2019-12-02 주식회사 종근당 Pharmaceutical composition for controlled release comprising Mirabegron or its salts
KR101868438B1 (en) 2017-04-13 2018-06-20 (주) 성운파마코피아 Method for preparing amide derivatives
WO2018221291A1 (en) 2017-05-31 2018-12-06 Ｓｂｉファーマ株式会社 Prophylactic or therapeutic agent for hyperactive bladder
KR102398639B1 (en) 2017-06-20 2022-05-17 (주) 성운파마코피아 Salts of amide derivatives and method for preparing the same
WO2019013583A2 (en) 2017-07-14 2019-01-17 주식회사 대웅제약 Pharmaceutical preparation and preparation method therefor
KR101937713B1 (en) 2017-07-14 2019-01-14 주식회사 대웅제약 Pharmaceutical formulation and preparation method for the same
KR20200117091A (en) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) Prodrug compound of mirabegron and its medical use for treating or alleviating overactive bladder diseases
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (en) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 Preparation method of (R) -2-hydroxy-N- [2- (4-aminophenyl) ethyl ] -2-phenethylamine
KR20220081033A (en) 2020-12-08 2022-06-15 주식회사 한서켐 Manufacturing method of α-type crystalline Mirabegron
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (en) 1989-09-28 1995-12-20 北陸製薬株式会社 Optically active benzyl alcohol derivative and its use
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (en) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenergic agent
AU6581294A (en) 1993-04-26 1994-11-21 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (en) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd New pharmaceutical use of beta3-adrenalin agonist
ATE239694T1 (en) 1995-10-26 2003-05-15 Mitsubishi Pharma Corp PHENYLETHANOLAMINE COMPOUNDS AND THEIR USE AS BETA3 AGONISTS, METHOD FOR THEIR PRODUCTION AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
CA2263659A1 (en) 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
US6630515B2 (en) 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
US6346532B1 (en) 1997-10-17 2002-02-12 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
HUP0100102A3 (en) 1997-12-18 2002-11-28 Kissei Pharmaceutical Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
DE69919860T2 (en) 1998-04-14 2005-08-25 Kissei Pharmaceutical Co., Ltd., Matsumoto 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICAL PREPARATIONS CONTAINING THEM
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
WO2000047771A2 (en) 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (en) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd 2-aminopropanol derivative
AU2710301A (en) 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (en) 2000-12-11 2004-06-16 Bayer Corp DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
WO2006102029A2 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence

Also Published As

Publication number Publication date
LU92218I2 (en) 2014-01-07
FR13C0032I2 (en) 2014-03-07
HUS1300027I1 (en) 2016-08-29
RU2005117367A (en) 2006-01-20
NO2015001I1 (en) 2015-01-19
US20060115540A1 (en) 2006-06-01
NZ539577A (en) 2007-06-29
DK1559427T3 (en) 2011-04-26
LU92218I9 (en) 2019-01-17
CY2013023I2 (en) 2015-10-07
ZA200503510B (en) 2006-12-27
MXPA05004925A (en) 2005-08-18
PT1559427E (en) 2011-05-27
IL168121A (en) 2011-12-29
CY2013023I1 (en) 2015-10-07
BE2013C040I2 (en) 2023-03-07
EP1559427A4 (en) 2007-05-30
AU2003284700B2 (en) 2009-05-28
KR100967070B1 (en) 2010-07-01
CY1111399T1 (en) 2015-08-05
US20110230530A1 (en) 2011-09-22
EP1559427A1 (en) 2005-08-03
US20090093529A1 (en) 2009-04-09
EP1559427B1 (en) 2011-03-09
JP3815496B2 (en) 2006-08-30
PL211687B1 (en) 2012-06-29
NL300599I2 (en) 2017-01-03
US8835474B2 (en) 2014-09-16
NO20052691D0 (en) 2005-06-06
RU2321401C2 (en) 2008-04-10
CN1711085A (en) 2005-12-21
ATE500827T1 (en) 2011-03-15
ES2360353T3 (en) 2011-06-03
DE60336334D1 (en) 2011-04-21
KR20050072809A (en) 2005-07-12
CA2503570A1 (en) 2004-05-21
NO2015001I2 (en) 2015-01-26
BR0316080A (en) 2005-09-27
US7750029B2 (en) 2010-07-06
SI1559427T1 (en) 2011-06-30
AU2003284700A1 (en) 2004-06-07
PL376771A1 (en) 2006-01-09
NO20052691L (en) 2005-07-15
WO2004041276A1 (en) 2004-05-21
USRE44872E1 (en) 2014-04-29
NO334948B1 (en) 2014-08-04
CA2503570C (en) 2011-04-19
CN100406011C (en) 2008-07-30
JPWO2004041276A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
BE2019C547I2 (en)
BE2019C510I2 (en)
BE2018C021I2 (en)
BE2017C049I2 (en)
BE2016C040I2 (en)
BE2016C013I2 (en)
BE2018C018I2 (en)
BE2011C038I2 (en)
JP2003175026A5 (en)
JP2003238445A5 (en)
JP2003230593A5 (en)
JP2003137930A5 (en)
BRPI0215435A2 (en)
JP2003230184A5 (en)
JP2003232838A5 (en)
JP2003132607A5 (en)
JP2003249414A5 (en)
JP2003221617A5 (en)
JP2003225450A5 (en)
JP2003255980A5 (en)
JP2002322195A5 (en)
JP2003257261A5 (en)
JP2003236882A5 (en)
BR0315835A2 (en)
JP2003229372A5 (en)